Aristo Bio-tech and Lifescience Limited brings its IPO for Rs 1305.22 lakhs Issue opens on the 16th of January, 2023
New Delhi (India), January 16: Aristo Bio-tech and Lifescience Limited, a dedicated crop protection company providing best quality manufacturing, formulation, supply and packaging job work services for various pesticides, is coming up with its IPO for 18,12,800 shares to raise Rs 1305.22 lakhs.
The face value per equity share is ₹10 and the equity price per share will be ₹72, including a share premium of ₹62 per equity share. The lot size is of 1,600 equity shares. Out of the 18,12,800 shares, 8,60,800 shares are for the HNI quota, 8,60,800 shares are for the retail quota and 91,200 shares have been reserved under the market maker quota. The issue opens on the 16th January 2023 and will close on the 19th January, 2023. It will subsequently be listed on the NSE Emerge platform. The lead manager to the issue is Beeline Capital Advisors Private Limited and the registrar to the issue is Link Intime India Private Limited. Stepup Capital Advisors LLP is the advisor to the issue.
The net proceeds from the issue will be utilized towards the following objects:
1. To meet working capital requirement
2. General corporate purpose
3. To meet the issue expenses
Aristo Bio-tech and Lifescience Limited is a dedicated Crop Protection company providing best quality manufacturing, formulation, supply and packaging job work services for various pesticides, insecticides, herbicides, fungicides, plant growth regulators and a wide variety of other agrochemicals in India as well as for export to other countries. It has 182 products registered with CIB&RC and is an ISO 9000:2015 and SMERA SME3 certified company. Its state of the art agrochemical and pesticide formulation & packaging unit is located in Vadodara, Gujarat and has the latest quality control, manufacturing and packaging machinery and equipments. It supplies its products across 20 states in India and 15 countries. The company’s exports have increased on the account of low-cost, manufacturing, availability of technically trained manpower, seasonal domestic demand, overcapacity, competitive pricing and strong presence in generic pesticide manufacturing.
The company has shown consistent growth in its fiscals. For FY2022, the company registered a total revenue of ₹16,603 lakhs as compared to ₹16,723 lakhs in FY2021, while the total revenue for H1FY23 stood at ₹12,907 lakhs. It registered an EBITDA of ₹550 lakhs in FY2022 as compared to ₹436 lakhs in FY2021, while the EBITDA for H1FY2023 stood at ₹509 lakhs. For FY2022, its PAT was ₹146 lakhs as compared to ₹108 lakhs for FY2021, while PAT for H1FY2023 is ₹259 lakhs.
Mr Narendra Singh Barhat, Mrs Kusum Narendra Singh Barhat and Mr Ketankumar Harkantbhai Joshi are the promoters of the issue.
If you have any objection to this press release content, kindly contact firstname.lastname@example.org to notify us. We will respond and rectify the situation in the next 24 hours.